Xenon Pharmaceuticals Inc.
XENE
Rang in aandelen
#4417
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Aandeelprijs
$36.43
Marktkapitalisatie
$3.53B
Verandering (1 dag)
3.85%
Verandering (1 jaar)
-16.13%
Land
CA
Handel Xenon Pharmaceuticals Inc. (XENE)
Categorie
Healthcare
P/B-ratio voor Xenon Pharmaceuticals Inc. (XENE)
P/B-ratio op October 2026 TTM: 2.72
Volgens de meest recente financiële rapporten en aandelenkoers van Xenon Pharmaceuticals Inc. is de huidige P/B-ratio (TTM) 2.72. Eind 2023 had het bedrijf een P/B-ratio van 3.32.
P/B-ratiohistoriek voor Xenon Pharmaceuticals Inc. van 2011 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 2.72 | -32.72% |
| 2024 | 4.04 | 21.83% |
| 2023 | 3.32 | 0.35% |
| 2022 | 3.31 | 33.52% |
| 2021 | 2.48 | -20.08% |
| 2020 | 3.10 | -16.15% |
| 2019 | 3.70 | 211.56% |
| 2018 | 1.19 | -16.22% |
| 2017 | 1.42 | -24.13% |
| 2016 | 1.87 | -0.77% |
| 2015 | 1.88 | -50.05% |
| 2014 | 3.77 | -4.78% |
| 2013 | 3.96 | 257.29% |
| 2012 | 1.11 | 0.00% |
| 2011 | 0.00 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | 129.99% |
US
|
|
| 13.2547 | 387.66% |
US
|
|
| 4.208 | 54.82% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 127.46% |
NL
|
